Acasti Pharma Stock Z Score
| ACST Stock | USD 3.19 0.16 4.78% |
Acasti | Z Score |
Acasti Pharma Company Z Score Analysis
Acasti Pharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Acasti Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Acasti Pharma is extremely important. It helps to project a fair market value of Acasti Stock properly, considering its historical fundamentals such as Z Score. Since Acasti Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acasti Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acasti Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Acasti Pharma has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Acasti Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acasti Pharma from analyzing Acasti Pharma's financial statements. These drivers represent accounts that assess Acasti Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acasti Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 32.1M | 71.2M | 44.9M | 20.5M | 18.5M | 17.5M | |
| Enterprise Value | 18.0M | 20.3M | 14.9M | (6.9M) | (7.9M) | (7.5M) |
Acasti Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Acasti Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acasti Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acasti Pharma's value.| Shares | Bank Of America Corp | 2023-12-31 | 494.7 K | Two Sigma Securities, Llc | 2023-09-30 | 0.0 | Adar1 Capital Management Llc | 2023-12-31 | 34.5 K | Royal Bank Of Canada | 2023-12-31 | 31.6 K | Ubs Group Ag | 2023-12-31 | 5.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.9 K | Advisory Services Network, Llc | 2023-12-31 | 41.0 | Ica Group Wealth Management, Llc | 2023-12-31 | 9.0 | Nbc Securities Inc | 2023-09-30 | 2.0 | Td Waterhouse Canada Inc | 2023-12-31 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 |
Acasti Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0792 | ||||
| Current Valuation | 6.4 M | ||||
| Shares Outstanding | 9.4 M | ||||
| Shares Owned By Insiders | 16.02 % | ||||
| Shares Owned By Institutions | 12.13 % | ||||
| Number Of Shares Shorted | 1.41 K | ||||
| Price To Earning | 15.34 X | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 208.39 X | ||||
| Gross Profit | 120 K | ||||
| EBITDA | 15.85 M | ||||
| Net Income | (42.43 M) | ||||
| Cash And Equivalents | 38.39 M | ||||
| Cash Per Share | 0.86 X | ||||
| Total Debt | 485 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.13 X | ||||
| Book Value Per Share | 6.88 X | ||||
| Cash Flow From Operations | (15.91 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (5.68) X | ||||
| Target Price | 5.96 | ||||
| Beta | 1.53 | ||||
| Market Capitalization | 31.49 M | ||||
| Total Asset | 79.12 M | ||||
| Retained Earnings | (198.27 M) | ||||
| Working Capital | 25.88 M | ||||
| Current Asset | 11.33 M | ||||
| Current Liabilities | 1.14 M | ||||
| Net Asset | 79.12 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acasti Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Acasti Stock
| 0.78 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.88 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Acasti Stock
| 0.8 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.78 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.77 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.76 | ME | 23Andme Holding | PairCorr |
| 0.75 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acasti Pharma Piotroski F Score and Acasti Pharma Valuation analysis. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Acasti Stock analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.68) | Revenue Per Share 0.005 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.